PDCD1 and neoplasm: Exhausted T cells acquire heritable de novo methylation programs able to restrict T cell expansion and clonal diversity during PD-1 blockade treatment. A DNA-demethylating agent (Decitabine) improved T cell responses and tumor control during PD-1/PD-L1 blockade (114)